logo

Arvinas Inc. (ARVN)



Trade ARVN now with
  Date
  Headline
5/29/2020 8:58:47 AM Arvinas Releases Updated Dose Escalation Data From Clinical Trial Of PROTAC Protein Degrader ARV-110
7/29/2019 7:13:08 AM Arvinas Appoints Ronald Peck As Chief Medical Officer
6/25/2019 7:18:55 AM Arvinas Says FDA Clears IND For ARV-471, Expects To Begin Phase 1 Trial Expected In Q3
6/4/2019 7:03:09 AM Bayer, Arvinas To Launch JV To Develop Targeted Protein Degraders
4/2/2019 7:15:58 AM Arvinas Names Andy Crew As Chief Technology Officer And Ian Taylor As Chief Scientific Officer